Compliance
Customers don't need to clear documents through internal review or negotiate confidentiality before running an analysis.
For business consultancies
Serious antitrust depth, without building the team.
Taimet gives advisory and diligence practices enterprise-grade merger antitrust analysis - a full report in 10-25 minutes, with the structure and cited sources that belong in a professional deliverable.
The largest advisory firms are investing in dedicated antitrust teams and proprietary AI tools. For practices that can't make that investment, the question isn't whether to add regulatory depth. The question is how.
Client expectations moved faster than staffing models.
Regulatory risk analysis is now table stakes in M&A diligence, not an optional add-on. Clients want structured, defensible analysis of whether a transaction will face scrutiny, and they want it before the slide deck is printed. Larger advisory firms handle this with dedicated antitrust economists and former regulators. Smaller practices face a harder set of choices: hire specialists you can't keep utilized, subcontract to boutique law firms at rates that consume the engagement margin, or piece something together from a general-purpose LLM and hope no one asks about the methodology.
That last option is the most dangerous. General-purpose models are unreliable on antitrust in specific, verifiable ways: wrong merger guidelines, fabricated state law citations, plausible-sounding market descriptions that fall apart under scrutiny. The firm's reputation is on the line every time that output reaches a client. Taimet is built for the alternative: a structured, cited antitrust analysis in 10-25 minutes, tuned by a former senior state enforcer, with professional-grade output your team can stand behind.
How Taimet fits advisory and diligence practices
Expert-grade antitrust on public data - deliverable-ready, cross-industry, and faster than staffing the work.
Deliverable-ready analysis, not chat-transcript output
Taimet produces a full written report with an executive summary, market overlap analysis, vertical issues, enforcement context, and a scored outcome prediction, all structured for professional readers. The output reads like the work product of a specialist, not a raw AI response. Excerpt it in a client memo, use the citations in a diligence deck, or use it as the foundation for a deeper regulatory workstream.
A prediction of the regulatory outcome - the answer clients need
Client deliverables need to answer the question behind the question: not just "is there antitrust risk?" but "what will regulators actually do?" The Taimet Score™ maps to six real-world outcome bands, from early termination through remedies to adverse decision. That gives your team a specific, defensible answer to anchor the client conversation, not a vague risk flag that raises more questions than it resolves.
The analytical depth of a specialist bench - without building one
The largest advisory firms staff former regulators and antitrust economists. Taimet encodes nearly two decades of real enforcement experience into every analysis: market identification, theories of harm, competitive effects, merger guidelines reasoning, state AG posture, and political context. A five-person advisory team gets the same analytical framework that a fifty-person practice deploys, applied automatically to every transaction.
Cited sources that hold up in front of client executives
Taimet sources its analysis from the public record: SEC filings, regulatory documents, trade publications, and news. When a client executive pushes back on a regulatory finding, your team has the citation trail to defend it - not ungrounded AI output, not black-box conclusions. Verification is built into the pipeline, so the sources in your work product connect to real, checkable materials.
Cross-industry coverage without sector-specific teams
CDD and transaction advisory work spans every sector: healthcare, semiconductors, energy, agriculture, financial services, retail. Larger firms maintain industry-specific practice groups to cover that breadth. Taimet applies the same structured analysis to any industry without sector-specific configuration - the system that handles a pharmaceutical merger handles a dairy cooperative, identifying the right analytical frameworks for each transaction automatically.
Win the pitch
Most firms say "we understand the deal." Few can demonstrate it immediately. Taimet lets you walk into a pitch with a structured, regulator-aware view already in hand - turning early insight into a commercial advantage.
Six bands, calibrated to real-world outcomes
Every analysis produces a 0-100 Taimet Score™, mapped to six interpretive bands. The bands are designed to reflect the actual range of merger outcomes - from quick clearance through trial on the merits to adverse decision - as an experienced attorney would predict them.
Score Ranges
Low riskHigh risk
1–25Early termination
Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition.
26–50Pull and refile
The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window.
51–70Second request
These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common.
71–85Remedies
A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation.
86–95Trial on the merits
Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits.
96–100Adverse decision
Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
1 to 25, Early termination: Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition. 26 to 50, Pull and refile: The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window. 51 to 70, Second request: These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common. 71 to 85, Remedies: A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation. 86 to 95, Trial on the merits: Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits. 96 to 100, Adverse decision: Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
Built by an enforcer who spent twenty years inside the work
Taimet's Founder, Gwendolyn Lindsay Cooley, served nearly two decades as Wisconsin's Assistant Attorney General for Antitrust. She chaired the National Association of Attorneys General Multistate Antitrust Task Force, leading coalitions of state and federal enforcers and collaborating with international counterparts. She co-led the trial team for the States' challenge to T-Mobile/Sprint - one of the highest-profile telecom antitrust cases in recent history.
Most AI products are built by AI researchers who consult lawyers. Taimet was built by a lawyer who spent two decades doing this work, in partnership with an engineer with two decades building production software. The reasoning encoded into the system isn't theoretical. It's hers.
Read more about Gwendolyn's background →
Things only an enforcer would know
There is a small body of working knowledge - the kind held by people who have spent years doing this - that determines how mergers actually get analyzed. None of it is in a textbook. Almost none of it is in an LLM's training data. All of it is in Taimet.
Pharmaceutical market definition
Small-molecule drugs are in the same market only if they share an identical molecular structure and are AB-rated for each other. Biologics are in the same market only if they’re biosimilars and treat the same disease. The distinction determines whether a pharma deal looks like a horizontal overlap or a non-issue. Most analysts don’t know it. Taimet does - and applies it automatically.
State enforcement patterns
Different state attorneys general challenge different kinds of mergers. Some are aggressive on hospital consolidation. Others on agriculture. Others on tech. Taimet knows which jurisdictions are likely to act on which transactions, which state-level enforcement theories apply, and which mergers will draw multistate coalitions.
Where the evidence actually lives
Pricing-power evidence often surfaces in investor presentations. Foreclosure intent shows up in board materials. Public statements about competitive intent surface in regulatory filings before they show up in press releases. Taimet knows where to look - because the person who designed it spent two decades looking there.
These are three examples among dozens. The full set is what makes the difference between an analysis that sounds expert and one that actually is.
An analyst that doesn't have to specialize
Taimet identifies the transaction structure automatically - horizontal, vertical, conglomerate, cross-market, cluster market, private equity, or any combination. Most real deals involve more than one structure at once. A private equity roll-up in a health services market may face horizontal overlap, vertical foreclosure concerns, and cumulative competition effects simultaneously. The system applies the right analytical frameworks for each without the user needing to classify the deal first.
Horizontal
Companies with overlap in both product and geographic market, competing directly in the same space.
Vertical
Companies in a direct or indirect vertical relationship within the same supply chain.
Conglomerate
An acquisition in an unrelated industry, with no economic relationship between the companies.
Cluster market
Multiple products sold together as a bundle (e.g., supermarket goods, hospital services).
Cross-market
Companies selling identical products but operating in separate, non-overlapping geographic markets.
Private equity
A private equity firm acquiring a company in a market where it has no existing holdings.
Across every industry
The FTC specializes. The DOJ specializes. Taimet doesn't.
Both federal agencies build their enforcement staffs around industry teams. A human analyst has to choose what to know deeply. That structural constraint doesn't apply to Taimet. The same system that analyzes a pharmaceutical merger - where market definition turns on molecular structure and AB-rating - analyzes a semiconductor deal, a regional hospital consolidation, or a mining joint venture. No configuration required. For the first time, the analytical breadth of the entire merger landscape is available to a single analyst.
PharmaceuticalsSemiconductorsHealthcare & HospitalsBig TechMining & ResourcesFinancial ServicesAgricultureReal EstateManufacturingTelecommunicationsRetail & Consumer GoodsEnergy & UtilitiesMedia & EntertainmentDefense & AerospaceTransportation & LogisticsFood & BeverageInsuranceBiotechnology
A screening tool, not a substitute for judgment
Taimet was designed first as an initial screening tool. For advisory and diligence practices, it adds enterprise-grade antitrust depth to client deliverables without requiring a specialist bench. Use it to underpin a CDD workstream, screen a client's acquisition pipeline, or build the regulatory section of a transaction advisory report.
But Taimet stops where human judgment begins. Consultants still advise their clients. Engagement teams still shape the deliverables. The system is built to sharpen expert judgment, not replace it - and every output is designed to be reviewed, challenged, and built upon by the human in the loop.
What Taimet does
- Analyzes broad and narrow market overlaps
- Reasons like an expert antitrust attorney
- Calculates HHI and estimated market shares
- Performs comprehensive vertical analysis
- Assesses state AG and political exposure
- Reviews related actions and prior conduct
- Predicts likely enforcement outcome with a 0-100 score
- Cites sources throughout
What Taimet doesn't do
- Conduct economic modeling (e.g., diversion ratios, merger simulation)
- Accept or process party-supplied documents
- Operate as a chatbot or interactive Q&A tool
- Replace the judgment of expert counsel, analysts, or enforcers
We only need the names of the companies
Taimet doesn't accept uploads. We don't process party-supplied documents. We don't ingest deal materials. To run an analysis, the system needs only the names of the merging companies. This serves three purposes at once:
Security
No party-confidential data ever enters the system, which means none can leak from it.
Anti-gaming
Taimet can't be used as a sandbox to reverse-engineer which factors lower a score. The integrity of the analysis can't be manipulated.
Hallucination is the central problem with using general-purpose LLMs for high-stakes legal and economic analysis. The errors sound plausible. They're hard for a human reviewer to catch. And once a wrong claim enters the pipeline, downstream analysis builds on top of it.
Taimet addresses this with verification passes throughout the analysis. Citation-checking agents confirm that claims are actually supported by the cited sources. Reasoning-consistency checks compare conclusions across agents. Claims without source support are flagged. Different stages of the pipeline cross-validate each other before the report is finalized.
The system checks its own work.
What practitioners are saying
“When you are reviewing multiple transactions with a small team, the constraint isn't judgment, it's time. A tool like this does not replace discretion, but it immediately shows you where to focus it.”
“Reflecting the creator's experience of regulatory matters, the depth of analysis, and more importantly the consistency, is far beyond anything we've seen from general tools. It's genuinely useful for investment decisions.”
“Even as antitrust enforcement becomes less predictable, the need for a clear, consistent view of risk hasn't gone away - if anything, it's more important. Taimet is one of the few tools that brings real structure to that uncertainty. We've been early believers, and it's become a critical part of how we advise investors in live situations.”
“Taimet is the first tool I've seen that genuinely closes the gap between legal analysis and investor needs. It delivers clarity where there used to be noise, and it's quickly become indispensable to how we advise our clients.”
Video WalkthroughSee how Taimet works,
See how Taimet works,
and how easy it is to use.
For consultancies
Antitrust depth that earns the engagement.
The largest advisory firms will build proprietary antitrust tools. For everyone else, there is Taimet: expert-grade analysis in 10-25 minutes, across any industry, with cited sources and a report structured for professional deliverables. Add real regulatory depth to your practice without the overhead of building a specialist team.
10-25 min
Full analysis, not a summary
0-100
Proprietary risk score
~15 hours saved
Per merger analysis
